Daratumumab treatment for immune-related blood clotting disorder
Part of Blood & lymphatic clinical trials.
This trial studies how well a drug called daratumumab works for a rare blood disorder (iTTP) that causes dangerous clots and low platelet counts. Researchers want to understand if this treatment helps patients recover and stay healthy long-term.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with iTTP (immune-mediated thrombotic thrombocytopenic purpura), confirmed by specific blood tests
- You are 18 years old or older
- You have already received or are receiving daratumumab treatment for your condition
- You are willing and able to give informed consent to participate
- You can commit to at least 6 months of follow-up visits or monitoring after starting daratumumab
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational antibody (anti-CD38) for older adults with ITP that hasn't improved with standard treatments. The goal is to see if this antibody can safely raise platelet counts and reduce bleeding risk.
This study compares daratumumab to rituximab for children with primary immune thrombocytopenia (ITP) that hasn't improved with steroids. The goal is to find a better treatment to raise platelet counts and reduce bleeding risk.
This trial tests a new antibody treatment (anti-CD38) for children ages 6 to 18 who have had low platelets for at least 3 months and did not improve with steroids. The goal is to see if this treatment can safely raise platelet counts.
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
This trial tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with long-term immune thrombocytopenia (ITP) who have already tried steroids without lasting success.
This study collects information from people with immune-mediated thrombotic thrombocytopenic purpura (iTTP) during an acute episode. It aims to better understand and improve care for this rare blood disorder.
Hear when a new Thrombotic Thrombocytopenic Purpura, Acquired trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.